专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明专利

PH12016501937A1 METHOD FOR IMPROVING SOLUBILITY OF PROTEIN AND PEPTIDE BY USING IMMUNOGLOBULIN FC FRAGMENT LINKAGE 未知
公开(公告)号：PH12016501937A1
公开(公告)日：2017-02-06
申请号：PH12016501937
申请日：2016-09-29
申请人： HANMI PHARM IND CO LTD
发明人： LIM HYUNG KYU , LEE JONG SOO , KIM DAE JIN , BAE SUNG MIN , JUNG SUNG YOUB , KWON SE CHANG
IPC分类号： C07K19/00 , C07K1/02
摘要： The present invention relates to: a method for improving the solubility of a physiologically active protein or peptide, compared to a physiologically active protein or peptide to which an immunoglobulin Fc fragment is not linked, comprising a step of linking the physiologically active protein or peptide to the immunoglobulin Fc fragment; and a composition for improving the solubility of a physiologically active protein or peptide, containing an immunoglobulin Fc fragment and exhibiting improved solubility compared with that of a composition not containing the immunoglobulin Fc fragment.

92. 发明专利

NO20161980A1 Method for decreasing immunogenicity of protein and peptide 未知
公开(公告)号：NO20161980A1
公开(公告)日：2016-12-14
申请号：NO20161980
申请日：2016-12-14
申请人： HANMI PHARM IND CO LTD
发明人： PARK SUNG HEE , KWON SE CHANG , CHOI IN YOUNG , LIM HYUNG KYU , KIM SEUNG SU , CHOI JAE HYUK
IPC分类号： A61K38/26 , A61K38/28 , A61K39/39 , A61K39/395
摘要： A method for increasing serum half-life of a protein or peptide and decreasing immunogenicity thereof is disclosed. The method includes site-specifically binding a carrier to a protein or peptide. A protein or peptide produced by the method and the uses thereof are disclosed. The conjugate of the physiologically active protein or peptide can significantly decrease immunogenicity in the human body and thus reduce antibody production rate against the protein or peptide. Therefore, the present conjugate has advantages in that a phenomenon of reduced clinical effects of the physiologically active protein or peptide is low, and it can be effectively used in the development of long-acting formulations having a high safety against the immune response.

93. 发明专利

MX2016003705A FORMULACION DE UN CONJUGADO DE HORMONA DEL CRECIMIENTO HUMANA DE ACCION PROLONGADA. 未知
公开(公告)号：MX2016003705A
公开(公告)日：2016-05-16
申请号：MX2016003705
申请日：2014-09-26
申请人： HANMI PHARM IND CO LTD
发明人： BAE SUNG MIN , KWON SE CHANG , LIM HYUNG KYU , KIM HYUN UK , KIM SANG YUN , RIM HWA PEOUNG , IM HO TAEK
IPC分类号： A61K9/19 , A61K38/25 , A61K38/27 , A61K47/30
摘要： La presente invención se refiere a una preparación de conjugado de hormona del crecimiento humana de tipo sostenido que comprende: un conjugado de la hormona del crecimiento humana (hGH) de tipo sostenido resultante de la conjugación entre la región Fc de inmunoglobulina y una hormona del crecimiento humana (hGH) que constituye un péptido bioactivo; una solución tampón; un tensioactivo no iónico; y un alcohol de azúcar. Más específicamente, la presente invención se refiere a una preparación liofilizada sostenida de conjugado de hormona del crecimiento de tipo humano y una preparación líquida, a un método de producción para la preparación liofilizada, a un método de reconstitución de la preparación liofilizada y a un kit que comprende la preparación liofilizada y a una solución de reconstitución.

94. 发明专利

HK1204291A1 A LIQUID FORMULATION OF LONG-ACTING INSULIN AND INSULINOTROPIC PEPTIDE 未知
公开(公告)号：HK1204291A1
公开(公告)日：2015-11-13
申请号：HK15104957
申请日：2015-05-26
申请人： HANMI PHARM IND CO LTD
发明人： LIM HYUNG KYU , KIM HYUN UK , LEE MI KYOUNG , LEE JONG SOO , BAE SUNG MIN , KWON SE CHANG
IPC分类号： A61K20060101
摘要： The present invention relates to a liquid formulation of a combination of long-acting insulin and insulinotropic peptide, comprising insulin which is a physiologically active peptide, insulinotropic peptide, and albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent; and a method for preparing the liquid formulation. The liquid formulation of the present invention does not contain a human serum albumin and potentially toxic factors to the body, and thus it has excellent storage stability for insulin conjugate and insulinotropic peptide conjugate at high concentration, without a risk of viral contamination.

95. 发明专利

AU2013293716A1 A liquid formulation of long acting insulinotropic peptide conjugate 未知
公开(公告)号：AU2013293716A1
公开(公告)日：2015-02-19
申请号：AU2013293716
申请日：2013-07-25
申请人： HANMI PHARM IND CO LTD
发明人： KIM HYUN UK , LIM HYUNG KYU , HONG SUNG HEE , KIM DAE JIN , BAE SUNG MIN , KWON SE CHANG
IPC分类号： A61K9/08 , A61K38/26 , A61K38/28 , A61K47/48
摘要： The present invention relates to a liquid formulation of long-acting insulinotropic peptide conjugate, comprising a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.

96. 发明专利

AU2013293718A1 A liquid formulation of long-acting insulin conjugate 未知
公开(公告)号：AU2013293718A1
公开(公告)日：2015-02-12
申请号：AU2013293718
申请日：2013-07-25
申请人： HANMI PHARM IND CO LTD
发明人： LIM HYUNG KYU , KIM HYUN UK , HONG SUNG HEE , KIM MIN YOUNG , BAE SUNG MIN , KWON SE CHANG
IPC分类号： A61K9/08 , A61K38/26 , A61K38/28 , A61K47/48
摘要： The present invention relates to a liquid formulation of long-acting insulin conjugate, comprising a pharmaceutically effective amount of a long-acting insulin conjugate, wherein a physiologically active peptide, which is an insulin, is linked to an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For preventing microbial contamination in multiple uses, a preservative can be added to the formulation. The liquid formulation of the present invention does not comprise a human serum albumin and potentially hazardous factors to body, and thus it has excellent storage stability for insulin conjugate without a risk of viral infection.

97. 发明专利

UA124182C2 СПОСІБ ПОКРАЩЕННЯ РОЗЧИННОСТІ ФІЗІОЛОГІЧНО АКТИВНОГО БІЛКА АБО ПЕПТИДУ 未知
公开(公告)号：UA124182C2
公开(公告)日：2021-08-04
申请号：UAA201610351
申请日：2015-03-31
申请人： HANMI PHARM IND CO LTD
发明人： LIM HYUNG KYU , LEE JONG SOO , BAE SUNG MIN , KIM DAE JIN , JUNG SUNG YOUB , KWON SE CHANG
摘要： Винахідстосуєтьсяспособупокращеннярозчинностіфізіологічноактивногобілкаабопептидупорівняноз фізіологічноактивнимбілкомабопептидом, некон’югованимз Fc-фрагментомімуноглобуліну, деспосібвключаєкон’югаціюфізіологічноактивногобілкаабопептидуз N-кінцем Fc-фрагментаімуноглобулінучерезнепептидильнийполімеррНвід 5,0 до 7,0, дефізіологічноактивнимбілкомабопептидомє ексендин-4, глюкагон, глюкагоноподібнийпептид-1 (GLP-1), глюкагоноподібнийпептид-2 (GLP-2) абооксинтомодулін, іденепептидильнийполімерє поліетиленгліколем.

98. 发明专利

NZ716251A Conjugate of biologically active polypeptide monomer and immunoglobulin fc fragment with reduced receptor-mediated clearance, and the method for preparing the same 未知
公开(公告)号：NZ716251A
公开(公告)日：2020-12-18
申请号：NZ71625114
申请日：2014-07-14
申请人： HANMI PHARM IND CO LTD
发明人： LIM HYUNG KYU , BAE SUNG MIN , KWON SE CHANG , JUNG SUNG YOUB , PARK SUNG HEE , KIM MIN YOUNG
IPC分类号： A61K38/26 , A61K39/395
摘要： The present invention relates to compositions of GLP1-1 Fc conjugates or insulin Fc- conjugates at a ratio of at least 19:1 monomers to dimers of fusion proteins that have reduced receptor mediated internalization or receptor medicated clearance that results in an increased serum half-life. Wherein the physiologically active polypeptide, used in the conjugate, is selected from the group consisting of glucagon-like peptide-1 (GLP-1), glucagon-like peptide-1(GLP-1) agonist, glucagon, oxyntomodulin, insulin, and derivatives thereof. The present invention relates to: a composition containing a conjugate having a bioactive polypeptide linked to an immunoglobulin Fc fragment, wherein the composition is a sustained pharmaceutical composition containing a monomer conjugate having one molecule of bioactive polypeptide linked to one immunoglobulin Fc fragment, and optionally a multimer conjugate having two or more molecules of identical bioactive polypeptide linked to one immunoglobulin Fc fragment, wherein the molar ratio of the monomer conjugate to the multimer conjugate in the composition is 19 or greater; a bioactive polypeptide monomer-immunoglobulin Fc fragment conjugate in which a bioactive polypeptide monomer and an immunoglobulin Fc fragment are linked via a non-peptide linker, wherein the bioactive polypeptide is linked, in a monomer form, to one immunoglobulin Fc fragment via the non-peptide linker, and demonstrates a lower receptor-mediated internalization or receptor-mediated clearance, compared to a dimer conjugate having two molecules of bioactive polypeptide linked to one immunoglobulin Fc fragment via a non-peptide polymer, or a bioactive polypeptide-immunoglobulin Fc fragment inframe conjugate; and a method for preparing the sustained pharmaceutical composition.

99. 发明专利

EA035964B1 СПОСОБ УМЕНЬШЕНИЯ ИММУНОГЕННОСТИ БЕЛКА И ПЕПТИДА 未知
公开(公告)号：EA035964B1
公开(公告)日：2020-09-07
申请号：EA201692279
申请日：2015-06-05
申请人： HANMI PHARM IND CO LTD
发明人： PARK SUNG HEE , KIM SEUNG SU , LIM HYUNG KYU , CHOI JAE HYUK , CHOI IN YOUNG , KWON SE CHANG
IPC分类号： C07K16/46 , A61K39/395 , A61P37/06
摘要： Изобретениеотноситсяк способуувеличениявремениполуэлиминациибелкаилипептидав сывороткеи уменьшенияихиммуногенностипосредствомсайт-специфическогосвязыванияносителяс белкомилипептидом, атакжек ихприменению. Конъюгатфизиологическиактивногобелкаилипептидапоизобретениюможетзначительноуменьшатьиммуногенностьв организмечеловекаи, такимобразом, снижатьуровеньпродуцированияантителпротивэтогобелкаилипептида. Следовательно, преимуществомнастоящегоконъюгатаявляетсято, чтоявлениеуменьшенияклиническогоэффектафизиологическиактивногобелкаилипептидаявляетсянизкими онможетбытьэффективноиспользованв разработкедлительнодействующихкомпозиций, обладающихвысокойустойчивостьюк иммунномуответу.

100. 发明专利

AU2020200626A1 Liquid Formulation Of Protein Conjugate Comprising The Oxyntomodulin And An Immunoglobulin Fragment 未知
公开(公告)号：AU2020200626A1
公开(公告)日：2020-02-20
申请号：AU2020200626
申请日：2020-01-29
申请人： HANMI PHARM IND CO LTD
发明人： LIM HYUNG KYU , JANG MYUNG HYUN , KIM SANG YUN , BAE SUNG MIN , KWON SE CHANG
IPC分类号： C07K14/605 , A61K9/08 , A61K38/26 , A61K39/395
摘要： The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the invivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection. In addition, the oxyntomodulin conjugate of the invention comprises oxyntomodulin linked to an immunoglobulin Fc region, and thus has a large molecular weight, prolonged physiological activity, and excellent storage stability, compared to native oxyntomodulin.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式